$UPB

Sutherland Everett Rand sold $13K of UPB

Sutherland Everett Rand (Chief Executive Officer) sold 2,095 shares of Upstream Bio, Inc. (UPB) at $6.10 on 2026-06-16.

Original reporting
SEC EDGAR · Sutherland Everett Rand
Published Jun 17, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$UPB
Bearish
medium confidence
Mentioned
$UPB
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UPBBearishLow
01

Why it matters

The newest disclosed fact is the CEO’s open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may briefly reassess sentiment around UPB due to CEO selling, but there is no fundamental catalyst in the text.

03

What to watch

The article does not state tax/option exercise context, and the small transaction value may be immaterial to valuation; also, absence of a 10b5-1 plan does not necessarily imply insider trading risk or negative fundamentals.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-17 (Form 4) for a sale dated 2026-06-16

Background

The article is an SEC Form 4 insider transaction disclosure for Upstream Bio, Inc. (UPB).

Company-level read

Ticker impact

$UPBBearishMedium confidence
Context

Upstream Bio CEO Sutherland Everett Rand sold 2,095 shares in an open-market transaction on 2026-06-16 at $6.10/share, per Form 4.

Expected impact

Likely limited near-term impact; could add slight downside bias if investors interpret as confidence signal.

Evidence & confidence

The filing is primary-source and time-stamped, but the dollar value (~$12.8k) is relatively small versus typical market moves, and no additional operational/regulatory catalyst is provided.

Market effects

No sector read-through; this is a company-specific insider transaction with no accompanying business update.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio management rather than a bearish view, especially since the filing provides no rationale or linkage to fundamentals.

Key entities

  • Upstream Bio, Inc.

    Issuer of the Form 4 insider transaction; CEO sold shares on 2026-06-16.

  • Sutherland Everett Rand

    CEO and officer/director who executed the open-market sale.

Related articles